In this supplement issue of Cell Transplantation featur-improvement in autonomic, motor, and sensory function. Frolov and Bryukhovetskiy elucidated the effect of ing the International Association of Neurorestoratology (IANR), 10 selected articles from the contributions for the autologous hematopoietic stem cells on 20 adult patients with chronic spinal cord injury at C4-C8 level using IANR IV and the 8th Global College of Neuroprotection and Neuroregeneration (GCNN) Conference are pub-motor and somatosensory evoked potentials test. Four positive findings were observed in 1-4 years after lished. The conference was held in Amman, Jordan on April 27 to 30, 2011 and hosted by the IANR, GCNN, repeated lumbar intrathecal transplantations, which included: 1) restoration of the initially absent short-and the American Society for Neural Therapy and Repair (ASNTR). The issue focuses on clinical translational med-latency SEP (three patients); 2) N20P23 interpeak amplitude increase in SEP elicited by median nerve icine in the field of Neurorestoratology, which provides further evidence for neurorestoration in humans.
stimulation ( treatment combined with T-cell vaccination might be a feasible, minimally invasive, safe approach for the treat-20 patients with early or late spontaneous recanalization but with persistent deficits and performed intra-arterial ment of amyotrophic lateral sclerosis (ALS) patients. They treated seven ALS patients with a result of slowing infusion of autologous bone marrow mononuclear cells between 3 and 7 days after stroke onset. Clinical, lab, or stopping disease progression. Chen et al. concluded that multiple doses of cellular therapy definitely serve electroencephalogram, and imaging evaluations showed no procedure-related adverse events. Satisfactory clini-as a positive role in the treatment of ALS, and the repeated and periodic cell-based therapy that the patients cal improvement occurred in 6/20 (30%) patients at 90 days. Eight patients (40%) showed a good outcome.
benefited from is strongly recommended for better controlling this progressive deterioration disorder. A total Huang et al. followed up a large sample of 108 patients with complete chronic SCI within 3.47 ± 1.12 of 42 patients underwent further OEC therapy by the route of key points for neural network restoration (KPNNR) years after olfactory ensheathing cell (OEC) therapy. No deterioration or complications were observed by clinical two or more times (twice in 35 patients, three times in five patients, four times in one patient, and five times in neurological functional evaluation, magnetic resonance imaging (MRI), electromyography (EMG), and paraver-one patient). All of them achieved partial neurological functional recovery after each cell-based administration. tebral sensory evoked potential (PVSEP). The data definitely demonstrated OEC therapy is safe and can Sharma et al. used autologous bone marrow-derived mononuclear cells in children with muscular dystrophy, improve neurological functions for patients with complete chronic SCI and ameliorate their quality of life, cerebral palsy, and injury to the brain and spine through intrathecal and intramuscular injection. On an average while the active movement-target enhancement-neurorehabilitation therapy plays a critical role in enhancing follow-up of 15 months, 97% of the muscular dystrophy cases showed subjective and functional improvement, functional repair after cell neurorestorotherapy. Wu et al. reported the clinical observation of OEC transplanta-with two of them also showing changes on MRI and three on EMG. One hundred percent of the spinal cord tion for complete chronic spinal cord injury. The improvement of moderate sensory, spasticity, and loco-injury cases showed improvement with respect to muscle power, urine control, and spasticity. Eighty-five per-motion occurred 14 months after cell therapy. Zhou et al. transplanted autologous activated Schwann cells cent of the cases of cerebral palsy cases showed improvements, out of which 75% reported improvement (AASCs) for six acute, subacute, and chronic spinal cord-injured patients [American Spinal Injury Associa-in muscle tone and 50% in speech among other symptoms. Luan et al. used neural progenitor cells to treat tion (ASIA) A, B, or C]. AASCs were harvested from the autologous sural nerve. The cells were implanted children with cerebral palsy (n = 45). Motor development significantly accelerated within the first month into the parenchyma of the cord following laminectomy. Within a 5-year follow-up, all of the patients had after cell transplantation, and further developmental S1 S2 HUANG level of gross motor, fine motor, and cognition was the medical community favor, not fear, the initial clinical endeavor and pioneering research of the field of higher compared with the controls after 1 year.
Taken together, the articles above show that the Neurorestoratology. I believe that support, encouragement, and normative research is what we should do, patients suffering from stroke, spinal cord injury, ALS, or cerebral palsy have a greater chance in further restor-rather than demand perfection for this new discipline. ing their neurological functions following the new concept of cell-based neurorestorotherapy and. interestingly, Hongyun Huang, M.D., Ph.D. Founding President over 30 different types of cells may have the potential for future clinical use. I hope more detail relating to the International Association of Neurorestoratology mechanisms of cell therapy can be elucidated and that
